I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

It is estimated that up to 50% of depressed patients either do not respond or only partially respond to an adequate course of antidepressant treatment.\[[@ref1][@ref2][@ref3]\] Consequently, augmentation strategies have been commonly used in treating major depression.\[[@ref4]\] Although the first generation antipsychotics (FGA) have been in use for treating major depression for a long time, their extrapyramidal side effects (EPS) have discouraged their use. Second generation antipsychotics (SGA) have become widespread in depression in the past decade due to the lower risk for EPS.\[[@ref5]\] A meta-analysis of sixteen trials with 3480 patients has found that SGAs are an effective augmentation treatment for major depression, but they are frequently discontinued due to adverse events.\[[@ref4]\] The US Food and Drug Administration have already approved the use of olanzapine (in combination with fluoxetine), aripiprazole (5--10 mg/d, maximum dosage 15 mg/d), and quetiapine extended release (50--300 mg/d) as adjunctive agents for depression.\[[@ref6]\] Most treatment guidelines recommend SGAs for augmentation in treating depression.\[[@ref6]\]

Regular cross-sectional surveys of prescription patterns are an efficient and fast way of obtaining a global picture of pharmacotherapy practice in a given setting.\[[@ref7]\] However, little is known about how antipsychotic medications are used over time in the treatment of depression in China where the mental health system is not only fundamentally different from other countries but has undergone rapid changes in the last decade. In a recent study of misdiagnosed bipolar patients receiving treatment for major depression, 19.2% of depressed Chinese patients received an antipsychotic drug.\[[@ref8]\] As the study only involved 13 major psychiatric hospitals or units, its findings cannot be generalized. Furthermore, the impact of antipsychotics on important outcomes such as patients' and their families' satisfaction with treatment and quality of life (QOL) was not explored.

Thus, this study aimed to: (1) Examine the prescription patterns of antipsychotic medications for depression across China nationally from 2002 to 2012; and (2) to explore the demographic and clinical correlates of adjunctive antipsychotic treatment and the association with treatment satisfaction and QOL.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study design and participants {#sec2-1}
-----------------------------

This was a cross-sectional nationwide pharmaco-epidemiological survey which was conducted in China initiated by the Chinese Society of Psychiatry. The first survey took place in May 2002 followed by another two surveys in May 2006 and July-August 2012 using the same design and standardized protocol. Consensus meetings on data collection and uniformity of data entry were held prior to each survey. A total of 45 psychiatric centers/units located in 10 provinces and municipalities including Beijing, Guangdong, Hebei, Hubei, Jiangxi, Jiangsu, Jilin, Shaanxi, Shanxi, and Sichuan participated in each survey. Districts were selected based on economic levels defined by the GDP report in 2000. The same 45 mental health centers/units were included in all the three surveys.\[[@ref9][@ref10]\]

One for every 14 inpatients and outpatients receiving treatment in the participating hospitals/units during the data collection period of 4 weeks were consecutively referred by their treating psychiatrists to the research team to be screened for eligibility. All members of the research team were attending psychiatrist with at least 3-year working experience. Inclusion criteria included: (1) DSM-IV or ICD-10 diagnosis of major depressive disorder (MDD) based on a clinical interview and review of medical records; (2) age 15 years or older; (3) ability to understand the aims and the contents of the survey. Those with comorbid psychotic disorders were excluded.

The study protocol was approved by the Ethics Committees of the participating centers. All patients provided written informed consent.

Assessments {#sec2-2}
-----------

Basic socio-demographic and clinical characteristics were collected using a form designed for the study. Information about the types and doses of psychotropic drugs were collected from the medical records.

Following the same procedures as in the Research on Asian Psychotropic Prescription project,\[[@ref11][@ref12]\] delusions, hallucinations, and suicidality in the past month were evaluated during the diagnostic interview. Global illness severity was evaluated with the Chinese version of the Clinical Global Impressions-Severity scale (CGI-S).\[[@ref13]\] The Treatment Emergent Symptom Scale (TESS)\[[@ref14]\] was used to record side effects. Patients and their families' satisfaction with the current treatment was evaluated with a self-rated, 7-point Likert scale, scoring from 1 (extreme dissatisfaction) to 7 (extreme satisfaction). QOL was assessed with the Chinese version of the Medical Outcomes Study Short Form 12 (SF-12).\[[@ref15][@ref16]\] The SF-12 is a multidimensional generic instrument with 12 items on physical and mental QOL domains. A higher score on SF-12 indicates better QOL.

In China, hospitals are classified into three levels according to the degree of specialization in clinical care and research. Level-III hospitals have the highest staff-patient ratio and medical resources while Level-II hospitals are regional medical centers that treat patients with severe diseases, and Level-I hospitals are small, community level hospitals providing basic medical care.\[[@ref17]\] There was no Level-I psychiatric hospital at the study time in the areas included, thus only Level-III/II medical facilities were included in this study.

All the 135 raters were trained in the use of the above-mentioned instruments. The inter-rater reliability of the instruments conducted in 20 MDD patients prior to the study yielded satisfactory to good agreement (\>0.75).

Statistical analysis {#sec2-3}
--------------------

The statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 20.0 (SPSS Inc., Chicago, IL, USA). In the pooled sample, comparisons between the antipsychotic and nonantipsychotic groups with respect to demographic and clinical variables were conducted with Chi-square tests, independent-samples *t*-test or Mann--Whitney *U*-test, as appropriate. Multiple logistic regression analysis with the "enter" method (i.e., all specified independent variables were entered at one time) was used to determine the demographic and clinical variables that were independently and significantly associated with antipsychotic use. Antipsychotic prescription was the dependent variable, while variables that significantly differed between the two groups in univariate analyses were entered as independent variables.

Patients and their families' satisfaction with the current treatment and QOL were only measured in the 2012 survey. In the 2012 sample, satisfaction with the current treatment and QOL were compared between the antipsychotic and nonantipsychotic groups after controlling for the potential confounding effects of variables that significantly differed between the two groups in univariate analyses using analysis of covariance (ANCOVA). Significance level was set at *P* \< 0.05 (two-tailed).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 4356 patients from 45 psychiatric hospitals/centers were screened for study entry; 3655 met the study criteria: 735 in 2002, 1389 in 2006, and 1531 in 2012, resulting in an overall participation rate of 83.9%.

The frequency of antipsychotic prescriptions was 24.9% (910/3655) in the whole sample; the corresponding figures were 17.1% (126/735) in 2002, 20.3% (282/1389) in 2006, and 32.8% (502/1531) in 2012 (*χ*^2^ = 90.3, df = 2, *P* \< 0.001). In the whole sample, the proportion of FGAs and SGAs was 6.1% (222/3655) and 19.4% (708/3655), respectively, with these figures being 12.4% (91/735) and 5.2% (38/735) in 2002, 6.9% (96/1389) and 14.2% (197/1389) in 2006, and 2.3% (35/1531) and 30.9% (473/1531) in 2012.

[Table 1](#T1){ref-type="table"} shows the socio-demographic and clinical characteristics of the whole sample and those of the antipsychotic and nonantipsychotic groups. [Table 2](#T2){ref-type="table"} displays the factors independently associated with antipsychotic prescription. Compared to the nonantipsychotic group, patients on antipsychotics had more delusions or hallucinations, significantly longer illness duration and higher TESS total score; were more likely to be inpatients and receive treatment in Level-III hospitals. These variables totally account for 26.9% of the variance of antipsychotic use (*P* \< 0.001).

###### 

Comparison between patients with or without adjunctive antipsychotic medication with respect to basic demographic and clinical variables during 2002--2012

  Variables                                                Total sample (*n* = 3655)   Nonantipsychotics (*n* = 2745)   Antipsychotics (*n* = 910)   Statistics   df     *P*
  -------------------------------------------------------- --------------------------- -------------------------------- ---------------------------- ------------ ------ ---------
  Male sex, *n* (%)                                        1305 (35.7)                 962 (35.0)                       343 (37.7)                   2.0^†^       1      0.140
  Inpatient, *n* (%)                                       1257 (34.4)                 794 (28.9)                       463 (50.9)                   145.9^†^     1      \<0.001
  Health insurance coverage, *n* (%)                       1893 (51.8)                 1348 (49.1)                      545 (59.9)                   31.8^†^      1      \<0.001
  Family history of psychiatric disorders, *n* (%)         537 (14.7)                  387 (14.1)                       150 (16.5)                   3.01^†^      1      0.070
  Delusions or hallucinations in the past month, *n* (%)   116 (3.2)                   14 (0.5)                         102 (11.2)                   254.5^†^     1      \<0.001
  Suicidality in the past month, *n* (%)                   878 (24.0)                  630 (23.0)                       248 (27.3)                   6.8^†^       1      0.008
  Hospital level, *n* (%)                                                                                                                                                
   Level-II                                                1791 (49)                   1377 (50.2)                      414 (45.5)                   5.9^†^       1      0.010
   Level-III                                               1864 (51)                   1368 (49.8)                      496 (54.5)                                       
  On FGAs, *n* (%)                                         222 (6.1)                   222 (24.4)                                                                        
  On SGAs, *n* (%)                                         708 (19.4)                  708 (77.8)                                                                        
  Age (years, mean ± SD)                                   42.3 ± 14.9                 42.1 ± 14.7                      42.8 ± 15.3                  −1.1^‡^      3653   0.230
  Age of onset (years, mean ± SD)                          38.4 ± 14.3                 38.6 ± 14.2                      37.8 ± 14.6                  1.4^‡^       3653   0.770
  Duration of illness (years, mean ± SD)                   3.8 ± 5.8                   3.5 ± 5.4                        4.8 ± 6.9                    −4.7^‡^      --\*   \<0.001
  CGI-S total (mean ± SD)                                  3.5 ± 1.4                   3.5 ± 1.4                        3.6 ± 1.3                    −2.6^‡^      --\*   0.008
  TESS total (mean ± SD)                                   0.8 ± 1.2                   0.7 ± 1.0                        1.1 ± 1.5                    −7.4^‡^      --\*   \<0.001

\*Mann--Whitney *U*-test; ^†^Chi-square values. ^‡^*t* values in independent-samples *t*-test or *Z* value in Mann--Whitney *U*-test. CGI-S: Clinical Global Impressions-Severity scale; FGAs: First generation antipsychotics; SGAs: Second generation antipsychotics; TESS: Treatment Emergent Symptom Scale; SD: Standard deviation.

###### 

Factors associated with antipsychotic prescription in MDD (*n* = 910)

  Factors                         *P*       *OR*   95% *CI*
  ------------------------------- --------- ------ ------------
  Inpatient status                \<0.001   2.3    1.9--2.8
  Health insurance coverage       0.490     1.06   0.8--1.2
  Delusions or hallucinations     \<0.001   32.0   17.4--58.7
   in the past month                               
  Suicidality in the past month   0.270     1.1    0.9--1.3
  Level-III hospital              \<0.001   1.6    1.3--2.0
  Duration of illness (years)     \<0.001   1.02   1.01--1.03
  CGI-S total                     0.780     1.01   0.9--1.1
  TESS total                      \<0.001   1.3    1.2--1.4
  Study time                                       
   2002                                     1.0    
   2006                           0.016     1.3    1.1--1.8
   2012                           \<0.001   2.6    2.0--3.4

Multiple logistic regression analysis with the nonantipsychotic group as the reference. Total *R*^2^=0.269, *P*\<0.001. CGI-S: Clinical Global Impressions-Severity scale; TESS: Treatment Emergent Symptom Scale; *OR*: Odds ratio; *CI*: Confidence interval; MDD: Major depressive disorder.

[Table 3](#T3){ref-type="table"} shows the socio-demographic and clinical characteristics, treatment satisfaction, and QOL in the 2012 sample, and separately according to antipsychotic prescription. After controlling for the potential confounding effects of variables that significantly differed between the two groups (inpatient status, presence of delusions or hallucinations and suicidality in the past month, hospital level, age of onset, duration of illness, and scores of CGI-S and TESS) using ANCOVA, antipsychotic use was associated with lower patients' (*F* ~(9,1521)~ = 12.4, *P* \< 0.001) and family\'s treatment satisfaction (*F* ~(9,1521)~ = 11.1, *P* = 0.001), while there was no significant difference with respect to physical (*F* ~(9,1521)~ = 1.7, *P* = 0.18) and mental QOL (*F* ~(9,1521)~ = 0.6, *P* = 0.42).

###### 

Comparison between the antipsychotic and nonantipsychotic groups with respect to basic demographic and clinical variables in 2012

  Variables                                                Total sample (*n* = 1531)   Nonantipsychotics (*n* = 1029)   Antipsychotics (*n* = 502)   Statistics   df     *P*
  -------------------------------------------------------- --------------------------- -------------------------------- ---------------------------- ------------ ------ ---------
  Male sex, *n* (%)                                        537 (35.1)                  357 (34.7)                       180 (35.9)                   0.2^†^       1      0.650
  Inpatient, *n* (%)                                       595 (38.9)                  323 (31.4)                       272 (54.2)                   73.7^†^      1      \<0.001
  Health insurance coverage, *n* (%)                       1129 (73.7)                 763 (74.1)                       366 (72.9)                   0.2^†^       1      0.600
  Family history of psychiatric disorders, *n* (%)         212 (13.8)                  129 (12.5)                       83 (16.5)                    4.5^†^       1      0.300
  Delusions or hallucinations in the past month, *n* (%)   42 (2.7)                    2 (0.2)                          40 (8.0)                     76.4^†^      1      \<0.001
  Suicidality in the past month, *n* (%)                   340 (22.2)                  213 (20.7)                       127 (25.3)                   4.1^†^       1      0.040
  Hospital level, *n* (%)                                                                                                                                                
   Level-II                                                645 (42.1)                  457 (44.4)                       188 (37.5)                   6.7^†^       1      0.010
   Level-III                                               886 (57.9)                  572 (55.6)                       314 (62.5)                                       
  Age (years, mean ± SD)                                   44.0 ± 14.9                 44.1 ± 14.8                      43.7 ± 15.2                  0.4^‡^       1529   0.660
  Age of onset (years, mean ± SD)                          39.3 ± 14.5                 39.8 ± 14.4                      38.2 ± 14.6                  1.9^‡^       1529   0.048
  Duration of illness (years, mean ± SD)                   4.8 ± 6.5                   4.5 ± 6.1                        5.5 ± 7.2                    −2.6^‡^      --\*   0.009
  CGI-S (mean ± SD)                                        3.4 ± 1.3                   3.4 ± 1.3                        3.6 ± 1.3                    −2.7^‡^      1529   0.006
  TESS total (mean ± SD)                                   0.9 ± 1.4                   0.8 ± 1.2                        1.1 ± 1.7                    −2.4^‡^      --\*   0.010
  Patients' satisfaction (mean ± SD)                       5.0 ± 0.9                   5.1 ± 0.9                        4.9 ± 0.9                    −4.5^‡^      --\*   \<0.001
  Families' satisfaction (mean ± SD)                       5.1 ± 0.9                   5.2 ± 0.9                        5.0 ± 0.8                    −4.1^‡^      --\*   \<0.001
  SF-12 physical (mean ± SD)                               46.4 ± 8.8                  46.4 ± 8.8                       46.4 ± 8.8                   0.04^‡^      1529   0.960
  SF-12 mental (mean ± SD)                                 32.5 ± 12.2                 33.2 ± 12.4                      30.8 ± 11.5                  3.6^‡^       1529   \<0.001

\*Mann--Whitney *U*-test; ^†^Chi-square values; ^‡^*t* values in independent-samples *t*-test or *Z* value in Mann--Whitney *U*-test. CGI-S: Clinical Global Impressions-Severity scale; SF-12: Medical Outcomes Study Short Form 12; TESS: Treatment Emergent Symptom Scale; SD: Standard deviation.

[Table 4](#T4){ref-type="table"} presents the frequently prescribed antipsychotic drugs across the three surveys. The first three most commonly prescribed antipsychotic drugs were sulpiride, perphenazine, and risperidone in 2002, olanzapine, risperidone, and quetiapine in 2006 and olanzapine, quetiapine, and risperidone in 2012.

###### 

The five most commonly prescribed antipsychotic drugs for MDD in China in year 2002, 2006, and 2012 (*n* (%))

  2002 (*n* = 126)   2006 (*n* = 282)   2012 (*n* = 502)                              
  ------------------ ------------------ ------------------ ----------- -------------- ------------
  Sulpiride          57 (45.2)          Olanzapine         66 (23.4)   Olanzapine     204 (40.6)
  Perphenazine       20 (15.9)          Risperidone        50 (17.7)   Quetiapine     162 (32.3)
  Risperidone        17 (13.5)          Quetiapine         47 (16.7)   Risperidone    58 (11.6)
  Clozapine          11 (8.7)           Sulpiride          38 (13.5)   Sulpiride      24 (4.8)
  Olanzapine         10 (7.9)           Perphenazine       33 (11.7)   Aripiprazole   19 (3.8)

Percentage of all patients on antipsychotic medications. MDD: Major depressive disorder.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The major finding of this study is that the overall frequency of antipsychotic use in treated MDD patients in China was 24.9% in the 2002--2012 period, which is slightly higher than found in another multicenter survey (19.2%) in Chinese depressed patients.\[[@ref8]\] The difference between the two studies may be due to the discrepancy in the number and types of institutions involved and diagnostic methods (a review of medical records and clinical interview versus the Mini International Neuropsychiatric Interview).

Another significant finding is the increase of adjunctive antipsychotic drugs from 17.1% in 2002, 20.3% in 2006 and to 32.8% in 2012. This increase might possibly be explained by the increasing use of SGAs and decreasing use of FGAs at the same time, the recommendations of SGAs in treating depression in clinical guidelines and the growing impact of pharmaceutical companies over the past decade.

As expected, one fifth of patients received SGAs in the sample with increasing proportion over time (5.2% in 2002, 14.2% in 2006, and 30.9% in 2012) while the proportion of FGA use decreased over time: 6.1% in the whole sample and 12.4% in 2002, 6.9% in 2006, and 2.3% in 2012. We assume that a number of socio-economic factors including local psychopharmacological practice, prior antipsychotic treatment, uneven access to antipsychotic drugs, insurance coverage, and costs might all contribute to such use in Chinese MDD patients. Considering the risk of antipsychotic-induced EPS and the absence of a clearly documented rationale, the use of FGAs should be discouraged in this population.

Olanzapine was the most commonly used SGA in Chinese MDD patients (7.7%), followed by quetiapine (5.7%), risperidone (3.4%), and aripiprazole (0.8%) in the pooled sample during the period between 2002 and 2012. Such practice appears consistent with the US FDA approval of two SGAs -- aripiprazole and extended release quetiapine-as adjunctive agents in antidepressant-resistant MDD in addition to olanzapine plus fluoxetine.\[[@ref6]\] However, the response to antidepressants could not be measured in this cross-sectional survey. A meta-analysis has found that there were no significant differences in efficacy between adjunctive olanzapine, risperidone, quetiapine, and aripiprazole in the treatment of MDD.\[[@ref4]\] The American Psychiatric Association guideline also does not differentiate between individual SGAs in its recommendations as add-on drugs for MDD.\[[@ref18]\]

In this study, concurrent antipsychotic use in MDD was associated with a number of clinical variables. Antipsychotics have been recommended mainly to be used in treatment-refractory MDD.\[[@ref4]\] This recommendation could explain the association of antipsychotic use with inpatient treatment, Level-III hospitals and longer duration of illness because these factors are more likely to be linked with treatment-resistance. The Chinese Medical Association\[[@ref19]\] recommended the concurrent use of antipsychotics in treating MDD with psychotic symptoms, which probably explains the association between antipsychotic prescriptions and delusions or hallucinations. As expected, concurrent use of antipsychotics was associated with more side effects as measured by the TESS.

Multivariate analyses revealed that compared to the nonantipsychotic group, MDD patients on antipsychotics was associated with poorer patients' and families' satisfaction with treatment. This may be attributed to more frequent adverse effects, higher cost of treatment, and reduced treatment adherence associated with antipsychotics.\[[@ref20][@ref21][@ref22]\] This association between severity of illness and dissatisfaction with the efficacy of the treatment could not be excluded. Surprisingly, however, there was no association between QOL and antipsychotic use, which could be partly attributed to the uncontrolled patients' and their families' economic level. This striking finding needs to be replicated in future studies.

There are several limitations to this study. First, due to its cross-sectional design, the causal relationship between concurrent antipsychotic use and other variables could not be examined. Second, the reasons for prescribing antipsychotics were not identified. There are differences in prescribing practices and treatment guidelines between institutions even within one province or municipality. Finally, the diagnosis of depression was established by a review of medical records and a clinical interview, rather than using a structured diagnostic interview schedule. These limitations are partly offset by the study\'s strengths including its large, homogeneous, and representative sample.

In conclusion, about one in four depressed patients received antipsychotic medication in this study, which has increased over time. Considering the increased risk of antipsychotic-induced side effects and patients' and their families' lack of satisfaction with psychiatric treatment in general, further examination of the rationale and appropriateness of antipsychotic prescription for depression and its alternatives is warranted.
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